Prostatype Genomics AB (SE:PROGEN)
:PROGEN
Want to see SE:PROGEN full AI Analyst Report?
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.28 - kr2.69
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr25.39M
Enterprise Valuekr6.11M
Total Cash (Recent Filing)kr12.93M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.20
Shares Outstanding59,189,320
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityZero reported debt materially reduces financial distress risk and preserves strategic flexibility. For a small diagnostics company burning cash, minimal leverage lowers near-term default risk and makes equity or partnership financing easier without servicing fixed interest, aiding durability.
Historical Revenue Growth PotentialA strong historical revenue growth rate indicates commercial traction for the Prostatype test offering and market receptivity. If the company can stabilize volumes and reimbursement pathways, this underlying demand supports scaling unit economics and longer-term margin improvement.
Reduced Cash Burn TrendA material reduction in cash burn year-over-year improves runway and lowers immediate refinancing pressure. Sustained discipline on operating costs combined with incremental revenue could convert the trend into durable cash-flow improvement and lessen reliance on dilutive financing.
Bears Say
Persistent Operating Losses / Weak MarginsDeep and recurring operating losses indicate the cost base outstrips current commercial revenue materially. Without sustained revenue scale or significant margin improvements, losses will continue to erode equity and require external funding, threatening long-term viability.
Negative Cash Flow And Reliance On FinancingConsistent negative operating and free cash flow means the company cannot self-fund growth or operations. Ongoing reliance on external financing exposes the business to dilution, funding availability risk, and potential disruption if capital markets tighten or partners withdraw support.
Very Small, Volatile Revenue BaseA small and unstable revenue base limits the firm's ability to absorb fixed costs, invest in commercialization, or negotiate payer coverage. This fragility makes long-term planning difficult and increases sensitivity to single-market reimbursements or a handful of customers.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.28 and its highest was kr2.69 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr25.39M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 89 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.397 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.397.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.397 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.907%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development of genomic tests aimed at improving the diagnosis and treatment of prostate cancer. The company operates in the healthcare sector, focusing on precision medicine by providing innovative genomic solutions that help clinicians make informed decisions regarding patient management and personalized treatment plans. PROGEN's core product is its proprietary genomic test, which analyzes tumor characteristics to predict disease progression and guide therapeutic choices for prostate cancer patients.